Is entrectinib an imported drug?

Entrectinib (Entrectinib) is indeed an imported drug. It was originally developed by the American company Ignyta and was acquired by Roche and further research and development was carried out. Roche is a world-renowned multinational pharmaceutical company with extensive influence in the pharmaceutical field. Entrectinib is a potent and selective inhibitor with central nervous system activity that crosses the blood-brain barrier and targets pan-TRK (tropomyosin receptor kinase) and ROS1 (a receptor tyrosine kinase encoding). Due to its potent inhibition of specific targets, entrectinib has shown promising efficacy against a variety of cancers in clinical trials.

In2019, entrectinib was approved for marketing in Japan, the United States, the European Union and other places, becoming a drug for the treatment of specific types of cancer. On July 29, 2022, entrectinib was also approved by the China National Medical Products Administration and was officially launched in China. This enables Chinese cancer patients to use this imported drug, thereby improving their treatment effects and quality of life.

Regarding the indications of entrectinib, it is mainly used to treat patients with solid tumors carryingNTRK fusion genes and patients with ROS1-positive advanced non-small cell lung cancer. The selection of these indications is based on a large amount of clinical trial data and medical research results, which prove that entrectinib has significant efficacy in these conditions.

In addition, the price of entrectinib is also a focus of concern for patients and doctors. Although its price is higher, many patients still choose to use entrectinib for treatment considering its efficacy and patient needs. At the same time, some countries and regions will also use medical insurance and other methods to reduce the financial burden of patients.